Comparisons of changes in circulating vascular endothelial growth factor-A and renal vascular parameters after intravitreal ranibizumab or aflibercept for retinal vascular disease

Comparisons of changes in circulating vascular endothelial growth factor-A and renal vascular parameters after intravitreal ranibizumab or aflibercept for retinal vascular disease - Comparisons of changes in circulating vascular endothelial growth factor-A and renal vascular parameters after intravitreal ranibizumab or aflibercept for retinal vascular disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036143

Enrollment

Registered

2019-03-10

Start date

2016-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration, diabetic macular edema, macular edema secondary to retinal vein occlusion

Interventions

Three monthly intravitreal injections of ranibizumab(0.5 mg/0.05 ml) Three monthly intravitreal injections of aflibercept(2.0 mg/0.05 ml)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who had not received prior intravitreal anti-VEGF therapy. 2)Patients with normoalbuminuria or microalbuminuria according to the 2012 Kidney Disease Improving Global Outcomes guideline(A1+A2 categories, KDIGO 2012).

Exclusion criteria

Exclusion criteria: 1)Patients who had received systemic anti-VEGF therapy for malignancy. 2)Patients who were currently on dialysis. 3)Patients who had undergone vitrectomy in the treated eye. 4)Patients who had severely high albuminuria (A3 category, KDIGO 2012).

Design outcomes

Primary

Measure	Time frame
Urine albumin to creatinine ratio 3 months after treatment	—

Secondary

Measure	Time frame
1)Circulating total VEGF-A and VEGF-A165b levels 3 months after treatment 2)Blood pressure 3 months after treatment 3)Ankle brachial index 3 months after treatment	—

Countries

Japan

Contacts

Public ContactShinsuke Ozawa

Tosei General Hospital Department of Ophthalmology

sp3n5xq9@jupiter.ocn.ne.jp0561-82-5101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026